Modern Setup Host Windows 10
Kroger Feedback

Blog

Live Blog: Valeant Pharmaceuticals – Acne Vulgaris: A Time to Challenge the Current View – Faculty: Hilary Baldwin, MD

In this live blog from the Annual Summer SDPA Conference in Las Vegas, Hilary Baldwin, MD, presented a product theater from Valeant Pharmaceuticals on Onexton (Clindamycin phosphate and benzoyl peroxide) Gel, 1.2%/3.75%, for the treatment of acne. Here are some of the highlights.

It is no surprise that acne vulgaris is the number 1 reason for visiting a dermatologist in the U.S. As the most common skin disorder in the U.S. affecting 40 to 50 million Americans, this condition does not spare any demographic. Clinics will treat across the board: teens boys and girls, adult males and females. In her product theater on Onexton (Clindamycin phosphate and benzoyl peroxide) Gel, 1.2%/3.75%, for the treatment of acne, Hilary Baldwin, MD, highlighted the adult female population as one eager and responsive recipient of this product.

Women over the age of 25 are coming into clinics around the country, many in distress over their acne. A 2014 study on lesion distribution in adult females showed the majority of facial acne involving multiple facial zones with mixed acne types (comedonal, noninflammatory, and inflammatory). These findings were contrary to the assumed belief that adult females primarily suffer from inflammatory acne in the “U-Zone.”

Additionally, another impact-focused study reported that three out of four adult females found their acne to be moderately to severely troublesome. Dr. Baldwin postulated that teen acne is better tolerated because of the commonality of the condition in the high school setting. “It’s more troublesome when you’re an adult in the workplace feeling alone in your condition,” she added. “We need to engage with and treat adult females as a separate patient-set from our teenage patients.” Adult women have particular factors contributing to their skin condition including menstrual flares, child bearing status, various underlying medical conditions, stress, and cosmetic usage. Luckily, recent studies point to positive outcomes for this specific population when treated with Onexton Gel daily for up to 12 weeks.

Indication

Onexton Gel is indicated for the topical treatment of acne vulgaris in patients 12 years of age or older.

Important Safety Information

  • Onexton Gel is contraindicated in patients with a known hypersensitivity to clindamycin, benzoyl peroxide, any component of the formulation, or lincomycin.
  • Onexton Gel is contraindicated in patients with a history of regional enteritis, ulcerative colitis, or antibiotic‐associated colitis.
  • Diarrhea, bloody diarrhea, and colitis (including pseudomembranous colitis) have been reported with the use of topical and systemic clindamycin. Onexton Gel should be discontinued if significant diarrhea occurs.
  • Orally and parenterally administered clindamycin has been associated with severe colitis, which may result in death.
  • Anaphylaxis, as well as other allergic reactions leading to hospitalizations, has been reported in postmarketing use of products containing clindamycin/benzoyl peroxide. If a patient develops symptoms of an allergic reaction such as swelling and shortness of breath, they should be instructed to discontinue use and contact a physician immediately.
  • The most common local adverse reactions experienced by patients in clinical trials were mild and moderate erythema, scaling, itching, burning and stinging.
  • Onexton Gel should not be used in combination with erythromycin‐containing products because of its clindamycin component.
  • Onexton Gel should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. A decision should be made whether to use Onexton Gel while nursing, taking into account the importance of the drug to the mother.
  • Patients should be advised to avoid contact with the eyes or mucous membranes.
  • Patients should minimize exposure to natural and avoid artificial sunlight (tanning beds or UVA/B treatment) while using Onexton Gel. To minimize exposure to sunlight, protective clothing should be worn and a sunscreen with SPF 15 rating or higher should be used.

Image: Marco




Our Sponsors